Inside the research
Insulet Corporation
PODD Research profile · latest available data
Price overview
$136.13
▲ +0.35 (+0.3%)
| 52w hi | $346.36 |
|---|---|
| 52w lo | $131.96 |
| Vol | 1.06M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.16
| Short | -0.59 |
|---|---|
| Medium | -0.06 |
| Long | +0.51 |
computed 2026-09-27
Key fundamentals
Insulet Corporation
Healthcare · Medical Devices
| Market cap | $9.44B |
|---|---|
| Enterprise value | $9.85B |
| Trailing P/E | 25.49x |
| Forward P/E | 17.66x |
| EV / EBITDA | 16.03x |
| P / S (ttm) | 3.09x |
| Profit margin | 12.3% |
| Return on equity | 26.0% |
| Revenue growth | +23.5% |
| Earnings growth | +328.6% |
| Debt / equity | 66.69 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.41 | |
| Sector | +0.08 | |
| Technical | -0.38 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Risk Metrics
| Beta vs SPX | 0.65 |
|---|---|
| Corr SPX | 0.25 |
| Annual vol | 41.2% |
| Annual ret | -19.1% |
| Sharpe | -0.46 |
| Max DD | -62.6% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $250.13 |
|---|---|
| High / Low | $360.00 / $175.00 |
| Median | $250.00 |
| Analysts | 23 |
| Strong Buy | 4 | |
|---|---|---|
| Buy | 16 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 1 |
Recent rating actions
| 2026-05-08 | Barclays | → Underweight |
| 2026-05-07 | Wells Fargo | → Overweight |
| 2026-05-07 | Truist Securities | → Buy |
| 2026-05-07 | RBC Capital | → Outperform |
| 2026-05-07 | Oppenheimer | → Outperform |
| 2026-05-07 | JP Morgan | → Overweight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-05 | Earnings Release, Exhibits | read |
| 2026-06-25 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-05-26 | Reg FD Disclosure, Exhibits | read |
| 2026-05-21 | Bylaws Amendment, Shareholder Vote… | read |
| 2026-05-06 | Earnings Release, Exhibits | read |
| 2026-04-29 | Reg FD Disclosure, Exhibits | read |
| 2026-03-12 | Reg FD Disclosure, Exhibits | read |
| 2026-03-04 | Officer / Director Change | read |
| 2026-02-18 | Earnings Release, Reg FD Disclosure… | read |
| 2026-02-03 | Material Agreement, Exhibits | read |
| 2025-12-19 | Auditor Change, Exhibits | read |
| 2025-12-17 | Officer / Director Change, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-01 | Davis Lisa Blair | SVP, Chief HR Officer | Withheld for tax | 244 | $40.35K |
| 2026-07-01 | MAZELSKY JONATHAN JAY | Grant | 1.35K | — | |
| 2026-06-30 | Huffines Robert Luther | Grant | 144 | $23.01K | |
| 2026-06-03 | STONESIFER TIMOTHY C. | Buy | 2.79K | $400.39K | |
| 2026-06-03 | BORIO LUCIANA | Sell | 418 | $59.89K | |
| 2026-06-03 | WEATHERMAN ELIZABETH H | Buy | 3.45K | $497.49K | |
| 2026-05-20 | WEATHERMAN ELIZABETH H | Grant | 1.66K | — | |
| 2026-05-20 | STONESIFER TIMOTHY C. | Grant | 1.66K | — | |
| 2026-05-20 | Scannell Timothy J | Grant | 1.66K | — | |
| 2026-05-20 | MINOGUE MICHAEL R | Grant | 1.66K | — |
Flow & Concentration
| Insider 180d net | $838.00K |
|---|---|
| Insider buys / sells | 2 / 1 |
| Insider bias | Neutral |
| 13F holders | 9 |
| Top-5 share | 90.2% |
| HHI | 2,224 (moderate) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $486.83M | 3.20M |
| AQR Capital Management | $373.79M | 2.46M |
| Fidelity / FMR LLC | $146.81M | 964.30K |
| Millennium Management | $131.76M | 865.39K |
| Citadel Advisors | $131.20M | 861.75K |
| Capital Research / Capital World | $83.41M | 547.82K |
| Renaissance Technologies | $30.77M | 202.08K |
| Bridgewater Associates | $23.81M | 156.41K |
| T. Rowe Price Group | $32.63K | 214.35K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $2.71B | +22.8% | |
| Gross profit | $1.16B | +34.5% | |
| Operating income | $473.80M | +60.8% | |
| Net income | $206.30M | +99.2% | |
| Cash from ops | $145.70M | +60.3% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $135.78 | $138.06 | $134.48 | $136.13 | 1.06M |
| Sep 24 | $136.80 | $139.35 | $134.55 | $135.78 | 1.09M |
| Sep 23 | $139.07 | $139.82 | $134.73 | $136.49 | 1.02M |
| Sep 22 | $141.93 | $142.04 | $137.60 | $139.38 | 1.25M |
| Sep 21 | $140.60 | $141.49 | $138.59 | $140.53 | 1.34M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →